Browsing Tag
platinum-resistant ovarian cancer
7 posts
Why platinum-resistant ovarian cancer remains a high-stakes proving ground for CDH6-targeted ADCs
Can SIM0505 change NextCure’s oncology outlook? Read why platinum-resistant ovarian cancer is the key test case for 2026.
Why Context Therapeutics (NASDAQ: CNTX) jumped on CTIM-76 fast track status and what comes next
Context Therapeutics stock rose after CTIM-76 won FDA fast track status. Read what it means for CNTX, ovarian cancer strategy, and the June 2026 data catalyst.
How Persevere Therapeutics plans to reposition misetionamide in a crowded ovarian cancer pipeline
Persevere Therapeutics launches misetionamide ovarian cancer trial. Discover how its strategy could reshape treatment competition.
Innovent Biologics advances IBI354 into Phase 3 trial for HER2-expressing platinum-resistant ovarian cancer
Discover how Innovent Biologics is advancing IBI354, a novel HER2-targeted therapy, into Phase 3 trials to transform ovarian cancer treatment.
AbbVie’s ELAHERE demonstrates 32% reduction in death risk for ovarian cancer patients
A final analysis of the Phase 3 MIRASOL trial has confirmed that ELAHERE (mirvetuximab soravtansine-gynx) provides a significant…
FDA grants full approval to AbbVie’s ovarian cancer drug ELAHERE
AbbVie (NYSE: ABBV) has achieved a significant milestone in the fight against ovarian cancer with the U.S. Food…
Aravive Biologics’ AVB-S6-500 receives FDA fast track designation for ovarian cancer
Aravive Biologics, a biopharmaceutical company, has received Fast Track designation from the U.S. Food and Drug Administration (FDA)…